Praxis Precision Medicines is not giving up on ulixacaltamide in essential tremor (ET) after the independent data monitoring committee (IDMC) for the Phase III Essential3 program said one of the program’s studies is unlikely to meet its primary endpoint and recommended stopping it for futility.
Praxis Aims To Complete ET Trial Despite Likely Primary Endpoint Miss
The Essential3 program’s data monitoring committee recommended stopping one of the essential tremor studies for futility, but the company said it will continue the trials anyway.
